

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Value Convergence Holdings Limited

(Incorporated in Hong Kong with limited liability)

Website: <http://www.vcgroup.com.hk>

(Stock Code: 821)

DISCLOSURE PURSUANT TO RULES 13.13 AND 13.15 OF THE LISTING RULES

This announcement is made pursuant to Rules 13.13 and 13.15 of the Listing Rules.

Under Rule 13.13 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), a general disclosure obligation arises where the relevant advance to an entity (as defined under Rule 13.11(2) of the Listing Rules) by Value Convergence Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and its subsidiaries exceeds 8% of the assets ratio as defined under Rule 14.07(1) of the Listing Rules (the “**Assets Ratio**”).

VC Brokerage Limited (“**VC Brokerage**”), a wholly-owned subsidiary of the Company, has made advances on normal commercial terms to two entities primarily to subscribe for shares in a company under an initial public offer (“**IPO**”) on the Stock Exchange. All the advances were made in the ordinary and usual course of business of the Company.

The advances were made on the basis of VC Brokerage’s credit assessments made on the respective clients’ financial strength, repayment ability and securities collateral provided. The likely popularity and liquidity of the relevant stock to be listed and the relatively short term nature of such advances were further considered. The Company expects that the full value of the IPO shares when allotted would be collateralised. Any collateral provided by the relevant entities for IPO financing will not be released by VC Brokerage unless and until all sums due and owing to VC Brokerage either have been fully repaid by the relevant entities or continue to be fully covered by the remaining collateral. After taking into account the factors as disclosed above in assessing the risks of the relevant advances, the Company considers that the risks involved in each of the advances to the entities as set out below are relatively low. The applicable interest rates were equivalent to those charged to other borrowers of similar financial standing.

Advances to entities exceeding 8% under the Assets Ratio

As at 4 June 2015, VC Brokerage had made advance to the following entities, details of which are set out as below:

Client	Approximate amount of the advance as at 4 June 2015 (HK\$)	Approximate % of the advance to the published audited total assets of the Group as at 31 December 2014	Approximate % of the advance to the published audited net assets value of the Group as at 31 December 2014	Nature of advance
Entity CL	82.7 million	13.1%	16.5%	IPO financing for 3SBio Inc. (Stock code: 1530) (“3SBIO”)
Entity CQ	82.7 million	13.1%	16.5%	IPO financing for 3SBIO

To the best knowledge, information and belief of the directors of the Company (the “**Directors**”), having made all reasonable enquiries, each of Entity CL and Entity CQ is third party independent of the Company and its connected persons (as defined under the Listing Rules). Entity CL and Entity CQ are high net worth individuals who have more than 11 years and 16 years of business relationship with VC Brokerage, respectively. Each of Entity CL and Entity CQ has never defaulted in repayment of any advances previously made by VC Brokerage.

The aforementioned advances made to Entity CL and Entity CQ are repayable in full on demand and are secured by the full value of the relevant IPO securities when allotted together with other listed securities and cash in the custody of VC Brokerage with collateral value of approximately HK\$315.4 million and HK\$103.5 million as at 4 June 2015 respectively; and are made at an interest rate lower than the prevailing prime lending rate of 5% as quoted by The Hong Kong and Shanghai Banking Corporation Limited. The financing periods in relation to the aforementioned advances are 6 days from 4 June 2015, the closing date of the IPO of 3SBIO, to the allotment date, which is expected to be on 10 June 2015.

As each of the advances as stated above exceeds 8% of the Company’s latest published audited consolidated total assets in the amount of approximately HK\$631.9 million as at 31 December 2014, the Company is under a general disclosure obligation under Rule 13.13 of the Listing Rules to disclose the same and certain particulars of each of such advances shall be disclosed under Rule 13.15 of the Listing Rules, unless a waiver from strict compliance with the same has been granted by the Stock Exchange (please refer to the section headed “Waiver from strict compliance with Rule 13.15 of the Listing Rules” below).

Waiver from strict compliance with Rule 13.15 of the Listing Rules

In respect of each of the aforementioned advances, the Company has applied for a waiver from strict compliance with Rule 13.15 of the Listing Rules in respect of the disclosure of the identities of the relevant entities and the actual interest rates in relation to each of the aforementioned advances made.

By order of the board of
Value Convergence Holdings Limited
Wong Yee Wah
Company Secretary

Hong Kong, 5 June 2015

As at the date of this announcement, the board of Directors comprises five Executive Directors, namely, Mr. Tin Ka Pak, Timmy (Chief Executive Officer), Mr. Chau King Fai, Philip, Mr. Cheng Tze Kit, Larry (Chief Investment Officer), Ms. So Wai Yee, Betty (Chief Financial Officer) and Mr. Lin Hoi Kwong, Aristo; one Non-executive Director, Mr. Chung Chi Shing, Eric; and three Independent Non-executive Directors, namely, Mr. Ip Chun Chung, Robert, Mr. Wong Chung Kin, Quentin and Mr. Wong Kam Choi, Kerry.